NANOTEKhNOLOGII V DIAGNOSTIKE I LEChENII ZLOKAChESTVENNYKh OPUKhOLEY


Cite item

Full Text

Abstract

Нанобиотехнология - активно развивающаяся область нанотехнологии, включает биомедицинское применение систем наноразмеров. Наноматериалы размерами от 1 до 1000 нм предоставляют возможность уникального взаимодействия с биологическими системами на молекулярном уровне, что может иметь большое значение при обнаружении, диагностике и лечении рака. Открывающиеся перспективы привели к образованию новой дисциплины - наноонкологии. Использование наночастиц - это новый метод таргетного воздействия, повышающий эффективность и снижающий токсичность как существующих, так и новых противоопухолевых препаратов. Ожидается, что в ближайшем будущем внедрение нанотехнологий приведет к революционным изменениям не только в онкологии, но и в медицине в целом.

References

  1. Jain K. Nanotechnology in clinical laboratory diagnostics. Clin Chim Acta 2005;358:37-54.
  2. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005;5:161-71.
  3. Yezhelyev M, Morris C, Gao X, et al. Multiple profi ling of human breast cancer cell lines with quantum dots-Ab conjugates. Proc Am Assoc Cancer Res 2005;46:510 (abstr).
  4. Jain K. Personalised medicine for cancer: from drug development into clinical practice. Expert Opin Pharmacother 2005;6:1463-76.
  5. Chan P, Yuen T, Ruf F, et al. Method for multiplex cellular detection of mRNAs using quantum dot fl uorescent in situ hybridization. Nucleic Acids Res 2005;33:161.
  6. Fortina P, Kricka LJ, Surrey S, et al. Nanobiotechnology: the promise and reality of new approaches to molecular recognition. Trends Biotechnol 2005;23:168-73.
  7. Gao X, Cui Y, Levenson RM, et al. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004;22:969-76.
  8. Artemov D, Mori N, Okollie B, et al. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 2003;49:403-8.
  9. Batist G, Ramakrishman G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor effi cacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001;19:1444-54.
  10. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable effi cacy in a phase III trial of pegylated liposomal doxo rubicin HCL (Caelyxtm/DoxilR) versus conventional doxorubicin for fi rst-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-9.
  11. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803.
  12. Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005;23:6019-26.
  13. Ito A, Shinkai M, Honda H, Kobayashi T. Medical application of functionalized magnetic nanoparticles. J Biosci Bioeng 2005;100:1-11.
  14. Weissleder R, Hahn PF, Stark DD, et al. Superparamagnetic iron oxide: enhanced detection of focal splenic tumors with MR imaging. Radiology 1988;169:399-403.
  15. Hirsch LR, Staff ord RJ, Bankson J, et al. Nanoshell-mediated nearinfrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA 2003;100:13549-54.
  16. Vogel CL, Cobleigh MA, Tripathy D, et al. Effi cacy and safety of trastuzumab as a single agent in fi rst-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
  17. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
  18. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
  19. Sparano A, Makhson AN, Semiglazov V.F. et al. Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression without Additive Cardiotoxity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Antracycline Therapy: Results From a Randomized Phase III Study. J Clin Oncol 2009;27(27):4522-9.
  20. Theodoulou M, Campos SM, Batist G, et al. TLC D99 (Myocet) and Herceptin is safe in advanced breast cancer: fi nal cardiac safety and effi cacy analysis. Proc Am Soc Clin Oncol 2002;21:55a (abstr).
  21. Gelderblom H, Verweij, Nooter, K, et al. Cremaphor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-8.
  22. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from Taxol. J Clin Oncol 1990;8:1263-8.
  23. Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005;11:4136-43.
  24. O'Shaughnessy JA, Blum JL, Sandbach JF, et al. Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metastatic breast cancer. Breast Cancer Res Treat 2004:88:S65 (abstr 1070).
  25. Shenoy DB, Amiji MM. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm 2005;293:261-70.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies